EVO - Evotec SE
4.22
0.010 0.237%
Share volume: 21,000
Last Updated: 04-25-2025
Pharmaceutical Products/Pharmaceutical Preparations:
-0.10%
PREVIOUS CLOSE
CHG
CHG%
$4.21
0.01
0.00%
Fundamental analysis
8%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
20%
Performance
5 Days
3.18%
1 Month
27.49%
3 Months
-1.86%
6 Months
-1.86%
1 Year
-1.86%
2 Year
-1.86%
Key data
Stock price
$4.22
DAY RANGE
$4.04 - $4.22
52 WEEK RANGE
$2.84 - $4.47
52 WEEK CHANGE
-$1.86
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-21-2025
Company detail
CEO: Werner Lanthaler
Region: US
Website: evotec.com
Employees: 4,200
IPO year: 2008
Issue type:
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing
Region: US
Website: evotec.com
Employees: 4,200
IPO year: 2008
Issue type:
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing
Evotec SE operates as drug discovery and development partner for pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.
Recent news
